Announced Date: 2024-11-13 (November 13, 2024)
Licensor (Seller): Zhuhai Biotheus Inc (China)
Licensee (Buyer): BioNTech
.
Key Asset: PM8002 (BNT327)
Asset Modality: BsAbs (Bispecific antibody)
Asset Target: PD-L1 and VEGF-A
Potential Indication: advanced solid tumors
.
Scope of Authority:
Under the agreement of 2024,
With the acquisition, BioNTech will obtain full global rights to the late-stage clinical asset BNT327/PM8002, an investigational bispecific antibody targeting PD-L1 and VEGF-A.
Upon closing, BioNTech will gain full rights to Biotheus’ pipeline candidates and its in-house bispecific antibody drug conjugate capability. The acquisition will expand BioNTech’s footprint in China, adding a local research and development hub to conduct clinical trials. In addition, BioNTech will gain a state-of-the-art biologics manufacturing facility to contribute to its future global manufacturing and supply, and more than 300 Biotheus employees in R&D, manufacturing and enabling functions are expected to join the BioNTech workforce.
.
Payment Detail:
BioNTech will pay Biotheus shareholders
an upfront consideration of $800 million, predominantly in cash,
plus additional performance-based contingent payments of up to $150 million if certain milestones are met.
.
Link:
. BioNTech to Acquire Biotheus to Boost Oncology Strategy | BioNTech
. BioNTech Completes Acquisition of Biotheus | BioNTech
.
Chinese Name of Biotheus, 普米斯
One thought on “[China BD 2024] [China Biotech M&A] Biotheus and BioNTech Enters an Acquisition on PD-L1/VEGF-A BsAbs PM8002 (BNT327)”